Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BPD
|
|||
| Former ID |
DNCL002698
|
|||
| Drug Name |
Emepepimut-S
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
EMD Serono; Oncothyreon
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00828009) BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell LungCancer That Cannot Be Removed by Surgery. U.S. National Institutes of Health. | |||
| REF 2 | Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.